Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Progenitor cells are the natural sources of tissues throughout your body and remain present through adulthood. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our therapies use proprietary combinations of small-molecule drugs to cause dormant progenitor cells to multiply and create new cells. Our Progenitor Cell Activation (PCA) technology is founded on discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard, with contributions from Xiaolei Yin, Ph.D. and other members of the Karp Lab at Harvard and Brigham & Women’s Hospital

Contact Frequency Therapeutics
Visit Website